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ABSTRACT 
With the increased costs of drug development, pharmaceutical companies 
outsource most of drug development to contract research organizations (CROs) 
and academic research organizations (AROs). Given the importance of the 
relationship between the contracting organization and pharmaceutical 
companies, project management has become the hallmark in conducting clinical 
trials. The purpose of this project was to identify whether there are differences in 
the project management practices of CROs and AROs who conduct clinical trials. 
An electronic survey and follow up interview were administered to 134 CROs and 
15 AROs who provide clinical trial services to pharmaceutical and biotechnology 
companies. The survey collected information on the characteristics of project 
managers, the organization demographics, and project management within the 
organization. The survey demonstrated significant differences between the 
services provided (p<0.001 ), organization of project management teams 
iv 
(p=0.001 ), availability of project management standard operating procedures 
(SOPs), training of project managers (p<0.05), and salary of project managers 
(p=0.003). The overall response rate of the survey was 36%; thus, the full 
variance of project management practices may not have been obtained in this 
survey. These findings highlight some differences between AROs and CROs, 
and provide a foundation to learn more about project management at these 
organizations. 
v 
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BACKGROUND 
The productivity of pharmaceutical companies has been in decline over 
the last two decades [Cuatrecasas, 2006; Roth & Cuatrecasas, 201 0; Vernon, 
Golec, & DiMasi, 2009; DiMasi & Grabowski, 2007]. Much of this decline has 
been attributed to rising Research and Development (R&D) costs, and the 
increasingly complex and costly process of the U.S. Food and Drug 
Administration (FDA) approval. 
The cost of drug development has grown steadily from 1975, when the 
cost to bring a drug to the market was only $138 million USD [PhRMA, 2010, 
Tufts CSDD, 2011]. Currently, it is estimated that the cost to bring one drug to 
the market is approximately $1.3 billion USD and will take approximately 10 
years [PhRMA, 201 0]. The decrease in productivity and rise in costs are 
supported by data from a Pharmaceutical Research and Manufacturers of 
America Member (PhRMA) report, which indicated the approval of New 
Molecular Entities (NMEs) has been dwarfed by the number of new drug 
approvals since 1998 [201 0]. This delicate state of drug development is 
compounded by the fact that only one new medicine results from every 5,000-
10,000 compounds screened in biological assays [PhRMA, 201 0]. The total 
industry R&D spending has been rising steadily; between 2004 and 2009, 
spending rose from $47.6 billion to $65.3 billion U.S. dollars [PhRMA, 2010]. In 
addition, DiMasi and Grabowski reported only 2 in 10 approved medicines 
recoup R&D costs [2007]. 
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The issues surrounding the development costs of biologics are similar. 
The American Academy of Microbiologists (AAM) noted that development costs 
for a single biologic averaged nearly $1 billion dollars USD [2005]. This is 
primarily due to the complex manufacturing process; biologics require a living 
organism for their manufacture. Thus, these large, complex molecules are very 
sensitive, as opposed to small molecule drugs. This contributes to the high cost 
of treatment. For example, treatment with the breast cancer drug Herceptin® 
costs patients $60,000 USD annually [Waltz, 2010] . Thus, there is a general 
reluctance to pay high prices for vaccines, which results in low profit margins 
[AAM, 2005; DiMasi & Grabowski, 2007]. 
Medical device development is almost as costly as drug and biologic 
development. Pre-clinical development costs run as high as $20 million USD 
while clinical development costs averages at least $100 million US dollars 
(Kaplan, Baim, Smith, Feigal, Simons, Jefferys, Fogardy, Kuntz, & Leon, 2004; 
Jump, 201 0]. To reduce the high costs with medical device development, a 
considerable amount of funding is achieved through venture capital. According 
to one report, over $40 billion in venture capital has been invested in the medical 
device industry [Norman, Janes-Dabney, & Takes, 2002; Kaplan, 2007]. 
The intricacies of the clinical trial process are viewed by many as 
the rate-limiting step for new therapeutics prior to FDA approval. As the cost of 
each clinical trial phase increases further into the approval process, the 
probability of passing from each clinical trial phase decreases [Cuatrecaseas, 
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2006; Tufts CSDD, 2010; Rochon, Berger, & Gordon, 1998]. The probability 
from Phase I to approval is less than 20% [Tufts CSDD, 201 0]. Also, industry 
reports have revealed that in the past decade, subject recruitment and retention 
worsened while protocol complexity, trial length, and staff work burden have 
increased [PhRMA, 2010; Tufts CSDD, 2010; Roth & Cuatrecasas, 2010; Yusuf, 
2004]. In the case of medical devices, the FDA approval process can take 
approximately seven years in the United States, while approval may take only 
two years in Europe [Jump, 201 0] . 
In an attempt to reduce costs and to speed the approval process, 
pharmaceutical, biotechnology, and medical device companies seek to outsource 
the development process, to Contract Research Organizations (CROs) and 
Academic Research Organizations (AROs). [Carita, 2008; Abraham, 2009; 
Shuchman, 2007] . The Wall Street Journal reported that outsourcing accounts 
for 63% of the development process for pharmaceutical development (2011 ). 
While many CROs and AROs specialize in areas ranging from molecule 
development to the FDA approval process, the most common service provided 
by contract organizations involves clinical trial oversight processes. Revenue of 
CROs has been in the tens of billions of USD since 2007 [Shuchman, 2007; 
Calaprice, 2008; Carita , 2008]. The number of CROs has also grown 
considerably over the past decade. They vary in size and location from multi-
billion dollar corporations such as PAREXEL International Corporation, with 
thousands of employees, to small niche companies with fewer than 50 
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employees. While AROs tend to provide the same services as CROs, they more 
commonly provide scientific leadership through faculty who specialize in a certain 
therapeutic area. AROs commonly handle journal and publication requirements 
as well [Goldenberg, Spyropoulos, Halperin, Kessler, Schulman, Turpie, Skene, 
Cutler, & Hiat, 201 0; Hutson, 201 0; Abraham , 2009]. To date, there are fewer 
AROs than CROs. Similar to CROs, many AROs have clients such as Merck, 
Pfizer, and Bristol-Myers Squibb, among others [Goldenberg, et al , 201 0; Kaplan, 
et al; Hutson, 201 0; Abraham , 2009]. While most AROs strive to function 
similarly to CROs, there have been some suggestions that AROs should stay 
within a limited domain of the clinical trial process, proposing an ARO-CRO 
model [Goldenberg et al., 2011; Abraham, 2009]. One suggestion that 
Goldenberg et al offers is a model where the CRO would handle the larger, more 
expensive components of the clinical trial , such as data management or safety 
monitoring, while the ARO would be involved with components of the clinical trial 
process geared toward more physician-intensive facets of the clinical trial such 
as a Data Safety Monitoring Board (DSMB) or clinical event adjudication [2011 ]. 
Given the FDA's scrutiny of contracting clinical trials, and the fairly recent closing 
of the Mayo Clinic's ARO, there are many who feel that contracting clinical trials 
jeopardizes the quality of data to be submitted for approval [Hutson, 201 0]. 
Pierre Azoulay, of Massachusetts Institute of Technology's Sloan School of 
Management was quoted saying that CROs are "data-production sweatshops", 
where "everyone's focused on the data and all the incentives are to do the work 
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fast," rather than emphasizing information required to determine whether there is 
benefit from pursuing the drug further [Shuchman, 2007]. 
The efficiency of CROs and AROs to complete the drug development 
process is largely due to the project-oriented approach [Widener, 2008]. As a 
result, the field of project management, once thought as the hallmark for product 
development in industries such as aerospace, construction, and engineering, 
now includes the development of drug, biologics, and medical devices. In recent 
years, project management has become the crux for successfully completing 
clinical trials, especially since outsourcing has become the standard. As Aycock 
stated, regardless of whether the organization is a CRO or ARO, the success of 
the collaboration depends on the project manager [2008]. Others have noted 
that the relationship between the sponsor and contract organization depends 
primarily on the project manager. This person oversees the components of the 
clinical trial such as data management, subject retention, patient recruitment, 
safety, and clinical event adjudication, among others, and assures they are 
completed in alignment with the sponsor company's goals and requests [Aycock, 
2008; Calaprice, 2008; Widener, 2008]. 
There are many publications and opinions on the topic of project 
management and the criteria for successful project management. Some of these 
criteria include professional experience, creativity, and problem solving skills 
[Aycock, 2008; Sundgren & Styhre, 2003; Selby, Treffinger, Isaksen, Lauer, 
2004, Seigel & Kaemmerer, 1978]. The Project Management Institute's (PMI) 
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Project Management Body of Knowledge (PMBOK) Guide has defined a project 
as "a temporary endeavor undertaken to create a unique product, service, or 
result" [2008]. A clinical trial is applied to this discipline as the unique product 
being a drug, device, or biologic product for patients. The 'temporary endeavor' 
is considered the clinical trial, as this process has a definite beginning and 
definite end [Doganov & Yanev, 2006]. Additionally, the PMBOK defines project 
management, as "the application of knowledge, skills, tools, and techniques to 
meet the project requirements" [2008] . In the pharmaceutical and device 
industries, this principle of project management equates to the management of 
the development of a drug, device, or vaccine through the phases of the clinical 
trial process. 
The PMBOK also describes the knowledge areas necessary for project 
managers to ensure the successful completion of a project [2008]. These 
knowledge areas are project integration management (activities needed for 
project execution), project scope management (ensuring all work required for 
successful completion), time management (timely completion of the project), cost 
management (estimating, budgeting costs of the project), quality management 
(policies, objectives, and responsibilities that satisfy the needs of the project), 
human resource management (ensuring roles and responsibilities are assigned 
to project team), and risk management (increasing the probability and impact of 
positive events and decrease the probability and impact of negative events on a 
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project) [PMI, 2008]. Table 1 outlines the knowledge areas of a project 
management and how they are applied to clinical trials. 
Table 1. Project manager knowledge areas applied to clinical trials. 
Knowledge Area Clinical trial components 
Project Integration • Outlining the tasks necessary to 
complete the trial 
Scope • Ensuring all deliverables for trial 
completion are met 
Time Management • Trial timeline is maintained and does 
not go beyond client's expectations 
Cost Management • Successfully staying within trial budget. 
Quality Management • Regulatory policies, trial objectives, 
and data are of high standards. 
Human Resource Management • Project team has defined roles and 
responsibilities. 
Risk Management • Plan for unexpected events that can 
have positive or negative effect on trial 
outcome (high number of SUSARs, 
poor enrollment, early trial close due to 
promisinq interim analysis, etc.) 
Several studies of project management in drug development have 
examined to determine how these practices ensure successful project 
completion. Cooke-Davies conducted a study of PMBOK project management 
knowledge areas across several industries that included pharmaceutical R&D. It 
was reported that the pharmaceutical and biotechnology industries scored 
highest in the domains project scope and resource management [Cooke-Davies, 
2002]. The knowledge areas in which the pharmaceutical industry scored the 
lowest were team types, (how the organization matches the project team to the 
project) and project integration [Cooke-Davies, 2002]. Doganov and Yanev 
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described the difference in the amount of time it took to complete each 
deliverable of a project before and after implementing project management 
practices to a bioequivalence study. The authors found that the duration of each 
deliverable was 50% lower with project management systems in place [2006]. In 
2003, data from a survey administered by the Project Management Institute 
(PMI), which benchmarked project management in CROs and various sized 
pharmaceutical companies, revealed differences between project management 
practices and responsibilities at different organizations [2001]. In an analysis of 
the 2001 PMI survey, Wilson , McDonough, Allbee, and Nielsen reported that the 
CRO's project management model provided a greater opportunity for the 
involvement of upper management in projects, CRO project managers had 
strong academic preparation, and more CRO project managers were expected to 
manage multiple projects than project managers at pharmaceutical companies 
[2003] . 
Given that project management has been demonstrated to be of 
importance in conducting clinical trials at CROs and pharmaceutical companies, 
to date there has not been an analysis the similarities and differences of project 
management between CROs and AROs. Thus, this study was conducted to 
determine whether there are differences between project management practices 
at AROs and CROs. 
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METHODS AND MATERIALS 
An electronic survey consisting of 27 multiple-choice questions was 
developed to collect information to compare project management between CROs 
and AROs (Appendix). The scope of the survey was determined by key trends in 
clinical trial management [Spilker, 2009], the FDA's position on the roles and 
responsibilities of organizations who provide service to pharmaceutical 
companies [Longman, 2006; Shuchman, 2007; Carita, 2008; Widener, 2008], the 
PMBOK Guide [PMI, 2008], and a survey previously administered by the PMI's 
Pharmaceutical Specific Interest Group (SIG), to compare project management 
between CROs and pharmaceutical companies [PMI, 2001] . 
The survey included questions pertaining to the background and 
experience of project managers, the organization's demographics, the services 
the organization provides, the types of clinical trials currently conducted, the roles 
and responsibilities of project managers in the organization, and the training of 
project managers in the organization . For the purpose of this survey, a 'project' 
was defined as a single, unique clinical trial. 
The required sample size for this survey (N=121, a=0.05, Cl=95%) was 
calculated based on sample size calculations for survey research as reported by 
Bartlett, Kotrlik, & Higgins [2001 ]. A list of potential respondent organizations 
was assembled from contact information provided by the Halloran Consulting 
Group (CRO; n=195, ARO; n=2), and Internet searches for contacts at CROs 
from an online published CRO directory and AROs (CRO; n=9, ARO; n=11 ). 
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Duplicate organizations were removed prior to sending the invitation to 
participate. The target respondents for the survey were project managers at 
AROs and CROs. The survey was piloted for two weeks in June 2011. As a 
result of the pilot survey, several changes were made to the instrument. 
Data collection took place through an online survey, distributed via e-mail, 
starting in June 2011 and ending in August 2011. The e-mail included a direct 
link to the beginning of the survey on SurveyMonkey®. Survey respondents were 
assured of confidentiality, although they were given the opportunity to provide 
their contact information to be entered in a raffle to win a $1 00 American 
Express® gift card for completing the survey and to be contacted for an optional 
follow-up interview. Survey Monkey® assigned a unique respondent ID all 
surveys. 
Survey respondents were asked to consider a 'current project' as a unique 
clinical trial within their organization and to answer each question to the best of 
their ability, only leaving questions unanswered if they felt they could not be 
absolutely confident in their answer. The first question of the survey asked 
whether the respondent was a project manager. If the respondent answered yes, 
the survey continued to the next series of questions asking about the background 
and experience of the project manager. If the respondent answered 'No', the 
survey directed the individual to the series of questions regarding the 
Organization's demographics. The second question with survey logic asked 
whether the survey respondent's organization was considered a CRO, an ARO, 
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or neither. If the respondent's organization was neither, the survey was 
terminated with a page thanking them for their time and participation. 
Survey responses were summarized according to the organization type: 
AROs and CROs. The differences between these organizations were analyzed 
using chi-square statistics (a=0.05), using SAS version 9.1 (SAS Institute, Cary, 
North Carolina, USA). 
Survey respondents who provided their contact information and indicated 
they were willing to participate in a brief follow-up interview, were contacted for 
in-person and phone interviews in September 2011, and were offered the 
opportunity to win one of two $50 American Express® gift cards. 
Follow-up interview questions were developed based on the preliminary 
findings of the survey as of August 2011 (Appendix). Interview questions 
consisted of the topics of project management training within the organization, 
the relationship between the organization and sponsoring companies, the 
organization's incorporation of risk management in project planning, and the 
individual's personal opinion regarding risk management. Another series of 
questions asked about the satisfaction of the project manager with their roles and 
responsibilities, salary, and relationship between Clinical Research Associates 
(CRAs) and senior management. The interview questions for the in-person 
interview were identical to those asked during the phone interviews. Each 
interview was recorded only if the respondent gave permission, and recordings 
were kept in a secured location to ensure confidentiality. Organization names 
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and personal identifiers were not mentioned in the interviews, and organizations 
were referred to as "your/my organization" in discussions, in order to maintain 
confidentiality. Audio files and interview notes were labeled only by the date and 
time the interview was conducted as a secondary measure to ensure 
confidentiality of the interviews. In the event that specific organizational details 
were provided, these answers were edited to keep answers in general terms. 
Interviews varied in length from 20 minutes to 40 minutes depending on 
the interviewee's answers and the level of detail they were comfortable providing. 
The responses to interview questions were paraphrased and summarized 
according to the organization type (Appendix). 
RESULTS 
Survey Responses 
The objective for surveying the characteristics of project managers, 
organization demographics, and the integration of project management within the 
organization, was to be able to identify differences between project management 
at AROs and CROs. Two hundred and seventeen surveys were distributed to 
organizations providing clinical trial services. There were 131 survey responses. 
Fifty-three of the respondents were excluded from the analysis: 49 whose 
organization was neither an ARO nor CRO, and four respondents who left this 
question unanswered. In total, 78 survey responses were used as the basis for 
this analysis, which represents a usable response rate of 36%. 
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Responses according to organizational type are provided in Figure 1. 
There were a total of 31 respondents from AROs, 4 7 respondents from CROs, 
and 53 survey respondents who reported 'none of these' (Table 2, Appendix). 
Considering the proposed sample size of 121 , the number of responses obtained 
was 64% of the target sample size. This group of respondents was used to 
identify and compare the differences in project manager characteristics, 
organizational demographics, and project management within AROs and CROs. 
Figure 1. ARO and CRO survey responses. 
Characteristics of project managers 
• ARO 
• CRO 
• None of These 
The goal of the first series of survey questions was to identify whether 
there were differences in the experience and background of project managers at 
AROs and CROs. Characteristics of project managers who responded to the 
survey are provided in Table 3 (Appendix). Of the project managers surveyed, 
13 
fifty-seven percent and 81% were project managers from CROs and AROs 
respectively. 
Organization Demographics 
The purpose of surveying organization demographics was to identify 
whether there were general differences between AROs and CROs, and 
differences in the nature of projects performed. Survey responses pertaining to 
organization characteristics are summarized in Table 4 (Appendix). These 
include the therapeutic areas in which the organization specializes, types of 
ongoing trials, phases of ongoing projects, total number of employees, 
organizational structure, number of 'mega-trials', regions where cl inical trials are 
conducted , and services provided . With the exception of services provided, 
specifically, academic leadership, no significant differences in organizational 
demographics between AROs and CROs were identified. 
Most of the services provided by both AROs and CROs were similar, with 
the exception of academic leadership, as shown in Figure 2. Twenty three AROs 
(82%) reported that their organization offered Academic Leadership, as 
characterized by oversight of clinical trial design, monitoring, and analysis of data 
for publication [Goldenberg , 2010], while five CROs (12%) offered this service 
(p<0.001 ). 
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Figure 2. 
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Management, Commercial Operations, Global Project Leadership, and Legal 
Operations. 
Project Management within the Organization 
Sixteen separate factors were assessed to better understand how project 
management was integrated within each organization. These survey questions 
included the allocation of project managers and CRAs or project staff for various 
scenarios, the number of project managers and CRAs or project staff in the 
organization, the head of project management, the number of projects assigned 
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at one time, factors to determine how projects were prioritized, whether project 
management Standard Operating Procedures (SOPs) were utilized, whether 
there was training offered 011 SOPs or project management practices, turnover, 
roles and responsibilities of project managers, knowledge areas of project 
managers, and salary of project managers. There were no significant differences 
between project managers at AROs and CROs with respect to project 
integration, with the exception of title of the head of project management, 
utilization of project management SOPs, formal training offered, and annual 
salary, (Tables 5-9, Appendix). 
A major difference between the AROs and CROs was the hierarchy of the 
project management team, as shown in Figure 3. Nearly half, 42% of all 
respondents from CROs, indicated that the Vice President was the head of 
project management (p=0.006), while 52% of AROs reported that the Director 
was the head of project management. 
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Figure 3. Title of the head of the project management team. 
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The availability of project management-specific SOPs was assessed to 
understand whether AROs and CROs have standardized operating procedures 
for project managers in their organizations. The availability of SOPs for project 
managers differed significantly between the AROs and CROs (p=0.05), as 
illustrated in Figure 4. While 97% of CROs reported that their organization had 
SOPs in place for project managers, only 79% of AROs reported having SOPs 
available for project managers. Further, nearly 1 0% of ARO respondents were 
unsure as to whether their organization had project management SOPs in place 
within their organization. 
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Respondents who indicated their organization had project management 
SOPs in place, were then questioned as to whether formal training was offered to 
project managers for these procedures. The availability of formal training for 
project management SOPs differed significantly between AROs and CROs, as 
demonstrated in Figure 5 (p=0.002). Eighty-four percent of project managers 
from CROs indicated their organization offered formal training, while only 54% of 
project managers from AROs offered formal training for project management 
SOPs. 
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Figure 5. Formal training for project management SOPs in the organization. 
Yes 
Training Available 
*Statistical significance (p=0.002) 
No 
• ARO 
• CRO 
The purpose of inquiring about salary was to understand whether there 
were differences in the compensation of project managers between AROs and 
CROs. The distribution of salary between the AROs and CROs differed greatly 
(p= 0.003) with eight times more CRO project managers reporting an annual 
salary of greater than $100,000 USD as compared with project managers at 
AROs (Figure 6). The median salary range of a project manager at an ARO was 
$71 ,000-$80,000 annually, while the median annual salary of a project manager 
at a CRO was $91,000-$100,000 (Figure 6). In controlling for education and 
experience of project managers with respect to salary, the annual salary of 
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project managers at CROs remained higher than that of project managers at 
AROs (p<0.05). 
Figure 6. Approximate salary of a project manager in the organization . 
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In summary, whi le several differences between AROs and CROs were 
identified through the survey, overall , these organizations were more similar than 
was initially hypothesized. Based on these findings , an interview was conducted 
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to further assess whether differences between project management practices at 
AROs and CROs existed . A second objective of the interview was to examine 
whether any organizational complexities in project management existed within 
the organizations, such as the sponsor's project needs, personal opinions 
regarding the integration of project management, and differences in 
organizational culture that may influence how projects are managed. 
Interview 
At the conclusion of the survey, respondents were asked whether they 
would be willing to participate in a follow-up interview to further discuss their 
experience with project management and project management in their 
organization. The premise was that in addition to the survey, the interview would 
uncover additional differences in project management practices between AROs 
and CROs. Of those who completed the survey, 12 agreed to be contacted for a 
brief interview (ARO, n=6; CRO, n=6), and six (ARO, n=3; CRO, n=3) 
respondents agreed to the follow-up interview. Responses to the interview are 
paraphrased in Tables 10-16 (Appendix). 
Based on the survey results regarding the SOP training opportunities for 
project managers, the interviewees were asked to describe the training their 
organization offered to project managers. Eighty percent of interviewees 
reported a formal training process for project managers in their organization. The 
type of training varied from classroom-like sessions tailored to previous 
experience, to shadowing a more experienced project manager. One ARO 
21 
reported that all project managers in their organization had prior industry 
experience and were proficient in a particular therapeutic area, and as a result, 
this ARO expected their project managers to rely on their previous experience in 
lieu of offering formal training. 
To better understand the complexities of the relationships that AROs and 
CROs have with the sponsor companies, the interviewees were asked to 
describe their organization's relationships with their clients. Overall , each 
organization reported that the relationship with the sponsor was positive , and that 
they had worked with the same sponsor on several occasions. One ARO 
reported poor relationships between their organization and several sponsors in 
the past. This organization indicated the strained relationships were due to the 
sponsor's lack of understanding about the culture of academia. 
According to the PMBOK, risk management is one of the knowledge areas 
in which all project managers must be proficient [2008]. Results from the survey 
showed that both AROs and CROs tend to not offer risk management training to 
project managers because it was not considered an important knowledge area 
from project managers (Table 9, Appendix). In response to this, interviewees 
were asked whether risk management plans were in place for projects in the 
organization. The responses regarding risk management are summarized in 
Table 12 of the Appendix. Every organization interviewed indicated there was 
some type of risk management or contingency plan in place for projects in their 
organization because, these plans were important to the success of their 
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projects. Each organization indicated that risk management planning was done 
early in the lifecycle of the project, such as the request for proposal (RFP) stage. 
Survey data revealed no significant differences in the roles and 
responsibilities of project managers at AROs and CROs. Given this similarity 
between AROs and CROs, we wanted to see if the satisfaction in the allocation 
of responsibil ities between AROs and CROs differed. Table 13 outlines the main 
themes from the interviews with respect to the project managers' satisfaction with 
their roles in the organization (Appendix). All interviewees reported they were 
satisfied with the roles and responsibilities of the project managers in their 
organization. One ARO cited that the organization had standardized the project 
manager job-description five years ago, and since then the overall satisfaction of 
the responsibilities has improved tremendously. 
While the differences in the background of project managers and 
responsibilities of project managers did not differ between AROs and CROs, 
there was a significant difference in the salary. Given this observation , project 
managers were asked how satisfied they were with their roles and 
responsibilities considering their annual salary. The opinions regarding the roles 
and responsibilities with respect to salary are highlighted in Table 14. Generally, 
project managers from both CROs and AROs felt that they were compensated 
fairly with respect to their roles and responsibilities. Two project managers from 
AROs acknowledged that although their salary was less than the industry 
standard, they had other benefits that made up for the difference. 
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While project managers are integral to the success of project completion, 
GRAs are similar, as they are responsible for most of the communication 
between the sponsor and the site investigators. As such, communication 
between the project manager and GRA is paramount to clinical trial success. To 
gain a better understanding of the interaction between project managers and 
GRAs, interviewees were asked to summarize their overall satisfaction with their 
interactions with GRAs. Table 15 summarizes the satisfaction in communication 
between project managers and GRAs (Appendix). The overall satisfaction in the 
communication was positive for interviewees from both AROs and GROs. One 
project manager from a GRO indicated that interactions between project 
managers and GRAs were positive because almost every project manager in the 
organization had prior GRA experience. While all project managers reported 
overall satisfaction in communication with GRAs, some organizations have 
identified specific previous experience that is important to project managers' 
success. 
To better understand how project management is integrated within AROs 
and GROs, information regarding the support project managers received from 
senior management (to ensure successful project completion) was assessed. 
The interview responses regarding the relationship between project management 
and senior management are outlined in Table 16 (Appendix). Overall the general 
consensus was that the relationship between project managers and senior 
management was positive. An interviewee from an ARO explained that because 
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their organization was so small, senior management was able to be involved in · 
daily projects. A project manager from a CRO explained that senior 
management was somewhat involved, but a new process was being developed 
that would allow for more interaction with senior management. All project 
managers appeared to value the input from senior management. 
DISCUSSION 
These survey and interview findings suggest there are few differences 
exist between project management at AROs and CROs. 
In the pharmaceutical industry, there is a trend to partner with large CROs. 
For example, Pfizer has announced that the CRO ICON is a "preferred provider" 
for clinical trial services based on their expertise in program and project 
management (ACT, 2011 ). However, these survey and interview results imply 
that when considering an ARO or CRO for clinical trial project management 
services, few differences exist. Thus, for a pharmaceutical, biotechnology, or 
medical device company considering outsourcing clinical trial project 
management, these results do not suggest project management in CROs is 
superior to AROs and vice versa. 
To date, metrics surrounding AROs have not been published. However, 
our finding that the hierarchy of the project management team of CROs has 
project managers in close proximity to senior management, and an annual salary 
of near $100,000 replicates the analysis of the SIG survey by Wilson et al, which 
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this survey was based on [2001]. However, the difference in salary observed 
between AROs and CROs was somewhat in line with Hutson's observations of 
the availability in funds, as AROs tend to struggle to find financial footing [201 0]. 
The survey finding that AROs tend to offer more academic leadership than that of 
CROs is similar to the observation by Lopes, that AROs place emphasis on 
increasing knowledge to treat the patient, and enhance scientific knowledge, 
while CROs tend to emphasize maximizing returns on R&D investments [201 0]. 
These results may be explained by considering the sources of contact 
information. The sample obtained for the survey was a convenience sample, and 
not a random sample. Thus, we may not have obtained the full variance of 
project management practices from this survey and interview. It is very likely that 
many medium and small sized CROs were overlooked when collecting contact 
information. Also, there are many more CROs than AROs in the industry. While 
ARO and CRO contacts were obtained form outside the United States, in general 
fewer AROs exist than CROs. Another explanation for these survey and 
interview results is that participants self-selected to participate. In the case of the 
interview responses, it is possible that those who participated did so because 
they felt strongly about the topic of project management. 
There are several limitations of the survey and interview. First, as 
previously mentioned, the survey was sent to a convenience sample, and not a 
random sample. In future surveys, Internet forums for project management and 
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clinical trials on social media sites such as Linkedln may serve as a source of 
additional survey respondents in order to maximize the sample size obtained. 
Also, contact information for project managers was not always available for 
organizations. There were some senior manager survey respondents as well as 
business development respondents. As a result, it is likely that some answers 
may not have adequately reflected project management in the organization , 
introducing selection bias into the results. Finally, it is possible that 
misclassification in organization types may have existed in the survey results. 
For example, Colorado's CPC Clinical Research refers to their organization as an 
"Academic CRO". Although the definition of ARO and CRO were explained in 
the survey invitation and in the beginning of the survey, we can not exclude the 
possibility that misclassification bias is present in the results. 
This survey and interview focused on differences between project 
management at AROs and CROs. While the actual organizations were providing 
responses on their organization, future studies should include surveying 
pharmaceutical , biotechnology, and medical device companies on the 
satisfaction of project management at AROs and CROs for which they had 
partnered with . This could allow for the strengths and weaknesses of 
organizations to be identified and readily compared. 
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CONCLUSION 
This is the first extensive survey to assess the difference between 
AROs and CROs with respect to project management. This is also the first time 
that metrics on AROs have been obtained. Through a survey and brief interview, 
few differences between AROs and CROs in the discipline of project 
management were identified. Regardless, the realm of project management is 
vital in clinical trials, as the project manager is ultimately responsible for assuring 
the quality of the project is of highest standards, not just for one project, but for 
all, as this will contribute to the sustainability of the organization . Continued 
surveillance on the project management styles and trends in AROs and CROs 
will be useful in underscoring the differences between these organization types . 
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APPENDIX 
Table 2. ARO and CRO survey response rate. 
ARO, N(%) CRO, N(%) 
217 Surveys Distributed 
131 Survey Responses 
53 Responses did not qualify 
Survey Responses for analysis 31 (40) 47(60) 
Table 3. Project Manager Characteristics. 
ARO, N(%) CRO, N(%) 
Respondents who are project 
managers 
Yes 25(81) 27(57) 
No 6(19) 20(43) 
Answered Question 31 (1 00) 47(100) 
Question not answered 0 0 
Years at current organization 
0-5 11 (44) 9 (32) 
6-10 6 (24) 9 (32) 
11-15 2 (8) 4 (14) 
>15 6 (24) 6 (21) 
Answered Question 25(81 )A 28(60) 
Question not answered 6(19)A 19(40) 
Question not answered 6(19)A 20(43)A 
ABased on total number of respondents for that quest1on. 
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Table 3. Project Manager characteristics (cont). 
ARO, N(%) 
Highest Degree Obtained 
BA/BS 8(32) 
MAIMS 8(32) 
PhD 4(16) 
PharmD 0(0) 
MBA 0(0) 
DVM 0(0) 
MD 3(12) 
DO 0(6) 
Other 2(8) 
Answered Question 25(81 )A 
Question not answered 6(19)A 
Professional Certification 
PMP 0(0) 
CAPM o <6f 
PQMP 0 (0) 
PMI-SP 0 (0) 
PPMC 0(0) 
PMI-RMP 0 (0) 
Six-SiQma 0 (0) 
CCRP 5(33) 
CCRA 1(7) 
CCRC 4(27) 
CPI 0 (0) 
CTI 0 (0) 
Other 4(27) 
Answered Question 15(48)A 
Question not answered 16(52)A 
Experience in Project Management 
0-5 1 0(40) 
6-10 3(12) 
11-15 4(16) 
>15 8(32) 
Answered Question 25(81 )A 
Question not answered 6(19)A 
ABased on total number of respondents for that quest1on. 
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CRO, N(%) 
3( 1 0) 
8( 29) 
3 11) 
2 7) 
4 14) 
0 0) 
5 18) 
0 0) 
3 11) 
28(60)A 
19(40)A 
3 (23) 
0 0) 
0 0) 
0 0) 
0 0) 
0 0) 
2 15) 
2 (15) 
5 (39) 
3 (23) 
0 0) 
0 0) 
2 15) 
13(28)A 
34(72)A 
7(26) 
11 41) 
2(7) 
7(26) 
27(57)A 
20(43)A 
Table 4. Organization characteristics. 
ARO, N(%) CRO, N(%) 
Therapeutic Area* 
Cardiology 24 (86) 38 (88) 
E ndocri no logy 17 (61) 29 (67) 
GI/Hepatology 14 (50) 26 (61) 
Nephrology 11 (39) 24 (56) 
Neuroscience (CNS) 13(47) 29 (67) 
Oncology 14 (50) 34 (79) 
Hematology 11 (39) 23 (54) 
Ophthalmology 9 (32) 27 (63) 
Immunology 10 (36) 28 (65) 
Otolaryngology 8 (29) 9 (21) 
Infectious Diseases 13 (46) 32 (74) 
Pediatrics 14 (50) 27 (63) 
Other 5 (18) 6 (14) 
Answered Question 28(90)A 43(91 )A 
Question not answered 3(10)A 4(9)A 
Types of ongoing clinical trials & 
studies* 
Drugs/Biologics 27 (96) 42 (98) 
Medical Devices/Diagnostics 22 (79) 30 (70) 
Epidemiological Studies 10 (36) 19 (44) 
Answered Question 28(90)A 43(91 )A 
Question not answered 3(1 O)A 4(9)A 
Answered Question 27(87)A 42(89)A 
Question not answered 4(13)A 5( 11 )A 
ABased on total number of respondents for the question. 
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Table 4. Organization characteristics (cont). 
ARO, N(%) CRO, N(%) 
Phases of Current Clinical Trials 
within the Organization* 
I 16 (57) 30 (70) 
II 25 (89) 35 (81) 
Ill 25 (89) 34 (86) 
IV /Post-marketing 21 (75) 34 (79) 
Medical Devices/Diagnostics 19 (68) 23 (54) 
Pivotal Device Studies 9 (32) 17 (40) 
Device Pilot Studies 7 (25) 13 (30) 
NSR Studies (medical devices only) 4 (14) 6 (14) 
SR Studies (medical devices only) 6 (21) 5 (12) 
Combination Products 10 (36) 21 (49) 
(e.g. drug-coated stent) 
Answered Question 28(90)A 43(91 )A 
Question not answered 3(10)A 4(9)A 
Total Employees in the 
organization 
<250 15(54) 14(33) 
250-500 3(11) 4(9) 
>500 1 0(36) 25(58) 
Answered Question 28(90)A 43(91 )A 
Question not answered 3(10)A 4(9)A 
Organizational Structure 
Project-based (A) 4(15) 7(17) 
Matrix (B) 11(41) 23(55) 
Departmental (C) 9(33) 9(21) 
None of these 3(11) 3(7) 
Answered Question 27(87)A 42(89)A 
Question not answered 4(13)A 5(11)A 
*Answer option included "Please select all that apply". ABased on total 
number of respondents for the question. 
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Table 4. Organization characteristics (cont). 
ARO, N(%) CRO, N(%) 
Number of 'mega-trials' ongoing 
None 8(30) 20(48) 
1-3 7(26) 12(29) 
3-5 5(19) 1(2) 
>6 7(26) 9(21) 
Answered Question 27(87)" 42(89)" 
Question not answered 4(13)" 5( 11 )" 
Regions of ongoing clinical trials* 
USA 21 (75) 36 (84) 
Latin America 12 (43) 27 (63) 
Asia 15 (54) 27 (63) 
Europe 14 (50) 33 (77) 
Australia 13(47) 24 (56) 
Canada 14 (50) 30 (70) 
Answered Question 28(90)" 43(91 )" 
Question not answered 3(1 0)" 4(9)" 
*Answer opt1on 1ncluded "Please select all that apply". "Based on total 
number of respondents for each question. 
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Table 4. Organization characteristics (cont). 
ARO, N(%) CRO, N(%) 
Services Provided* 
Academic Leadership 23 (82) 5 (12) 
Laboratory Services & 5 (18) 10 (24) 
Manufacturing 
Steering Committee Leadership 17 (61) 20 (49) 
Study Design 22 (79) 35 (85) 
Site Recruitment 10 (36) 18 (44) 
Site Monitoring 14 (50) 35 (85) 
Adjudication Committee 10 (36) 18 (44) 
Specialty Facilities (i.e. core labs, 16 (57) 16 (39) 
etc.) 
Biostatistics 19 (68) 33 (81) 
Consultation on Product 19 (68) 33 (81) 
Development 
DSMB/DMC 18 (64) 21 (51) 
Analytical Testing 3 (11) 12 (29) 
IRB 14 (50) 5 (12) 
Data Management 20 (71) 39 (95) 
Pharmacovigilance/Safety 11 (39) 29 (71) 
Monitoring 
Regulatory Affairs 16 (57) 35 (85) 
Auditing 7 (25) 25 (61) 
Other 4 (14) 9 (22) 
Answered Question 28(90)A 41 (87)A 
Question not answered 3(10)A 6(13)A 
*Answer opt1on Included "Please select all that apply" . ABased on total 
number of respondents for that question. 
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Table 5. Project Manager allocation among AROs*at. 
Project Managers 
1 2 3 4 5 >5 Response 
Scenario N(%) N(%) N(%) N(%) N(%) N(%) Count 
Several 
countries with 1 (9) 6 (55) 2(18) 0(0) 1(9) 1(9) 11 
>1 0,000 
subjects 
Several 
countries with 5 (63) 2 (25) 0(0) 0(0) 1 (13) 0(0) 8 
1,000-10,000 
subjects 
Several 
countries with 8(100) 0(0) 0(0) 0(0) 0(0) 0(0) 8 
500-1,000 
subjects 
1 country with 
500-1,000 7(1 00) 0(0) 0(0) 0(0) 0(0) 0(0) 7 
subjects 
1 country with 8 (73) 3 (27) 0(0) 
<500 subjects 0(0) 0(0) 0(0) 11 
aPercentage is based on total number of respondents for the question (n=16, 
52%). 
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Table 6. CRA and Project Staff allocation among AROs*a. 
CRAs/Project Staff 
<5 5-10 10-15 15-20 >20 Response 
Scenario N(%) N(%) N(%) N(%) N(%) Count 
Several countries 
with >1 0,000 3(30) 2(20) 1 (1 0) 1 (10) 3(30) 10 
subjects 
Several countries 
with 1,000-10,000 4 (50) 2 (25) 1 (13) 0(0) 1 (13) 8 
subjects 
Several countries 
with 500-1 , 000 4 (57) 2 (29) 1 (14) 0(0) 0(0) 7 
subjects 
1 country with 500- 5 (57) 2 (20) 0(0) 0(0) 0(0) 7 1 ,000 subjects 
1 country with 7 (70) 2 (20) 0(0) 0(0) 1 (1 0) 10 
<500 subjects 
aPercentage IS based on total number of respondents for the quest1on (n=16, 
52%). 
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Table 7. Project Manager allocation among CROs*b. 
CRAs/Project Staff 
1 2 3 4 5 >5 Response 
Scenario N(%) N(%) N(%) N(%) N(%) N(%) Count 
Several 
countries with 1(5) 3(16) 3(16) 1(5) 2(11) 9(47) 19 
>1 0,000 
subjects 
Several 
countries with 3(14) 3(14) 7(33) 5(24) 1(5) 2(10) 21 1,000-10,000 
subjects 
Several 
countries with 8(35) 8(35) 4(17) 0(0) 1 (4) 2(9) 23 500-1,000 
subjects 
1 country with 
500-1,000 17(74) 4(17) 1 (4) 0(0) 0(0) 1(4) 23 
subjects 
1 country with 24(92) 1 (4) 0(0) 0(0) 0(0) 1 (4) 26 
<500 subjects 
bo 
-Percentage based on total number of respondents for the quest1on (n-30, 64%). 
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Table 8. CRA and Project Staff allocation among CROs*b. 
Project Managers 
<5 5-10 10-15 15-20 >20 Response 
Scenario N(%) N(%) N(%) N(%) N(%) Count 
Several countries 
with >1 0,000 0(0) 1 (5) 2 (11) 1(5) 15(0) 19 
subjects 
Several countries 
with 1,000-10,000 0(0) 2(1 0) 1(5) 5(24) 13(2) 21 
subjects 
Several countries 
with 500-1,000 1(5) 7(32) 4(18) 7(32) 3(14) 22 
subjects 
1 country with 500- 5(23) 7(32) 6 (27) 3(14) 1(5) 22 1 ,000 subjects 
1 country with 11 (46) 10 (42) 1 (4) 1 (4) 1 (4) 24 
<500 subjects 
01 
-
0 Percentage 1s based on total number of respondents (n-30, 64 Yo). 
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Table 9. Characteristics of Project Management within AROs and CROs 
ARO, N(%) CRO, N(%) 
Number of Project Managers 
employed in the organization 
0-5 9 (36) 12 (32) 
6-10 1 (4) 3 (8) 
11-15 4 (16) 2 (5) 
>15 11 (44) 21 (55) 
Answered Question 25(81 )" 38(81 )" 
Question not answered 6(19)" 9(19)" 
Title of head of project management 
in the organization 
Head/Manager 10 (40) 4 (11) 
Vice President 0 (0) 16 (42) 
Director 13 (52) 14 (37) 
Other 2 (8) 4 (11) 
Answered Question 25(81 )" 38(81)" 
Question not answered 6(19)" 9( 19)" 
Total number of project team 
members (i.e. CRAs, project 
assistants) employed 
0-10 11 (44) 7 (19) 
10-20 3 (12) 3 (8) 
>20 11 (44) 27 (73) 
Answered Question 25(81 )" 37(79)" 
Question not answered 6(19)" 1 0(21 )" 
Number of projects assigned to a 
Project Manager at one time 
1 4 (17) 4 (11) 
2 7 (30) 18 (47) 
3 4 (17) 8 (21) 
4 3 (13) 3 (8) 
>4 5 (22) 5 (13) 
Answered Question 23(74)" 38(81 )" 
Question not answered 8(26)" 9(19)" 
"Based on total number of respondents for each quest1on. 
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Table 9. Characteristics of Project Management within AROs and CROs (cont) 
ARO, N(%) CRO, N(%) 
Factors in prioritizing projects in 
the organization* 
Contract Value 7 (29) 17 (45) 
Margins 1 (4) 5 (13) 
Size of Project 10 (42) 23 (61) 
Duration of Project 2 (8) 8 (21) 
Projected Success of Project 4 (17) 4 (11) 
Resource Allocation for Project 7 (29) 12 (32) 
Other 9 (38) 7 (18) 
Answered Question 24(77)A 38(81 )A 
Question not answered 7(23)A 9(19)A 
SOPs implemented within the 
organization 
Yes 19 (79) 37 (98) 
No 3 (13) 1 (3) 
Not Sure 2 (8) 0 (0) 
Answered Question 24(77)A 38(81 )A 
Question not answered 7(23)A 9(19)A 
Formal training on SOPs, project 
management strategies, etc 
offered within the organization 
Yes 13 (54) 33 (89) 
No 11 (46) 4 (11) 
Answered Question 24(77)A 37(79)A 
Question not answered 7(23)A 1 0(21 )A 
*Answer opt1on mcluded "Please select all that apply". ABased on total 
number of respondents for each question. 
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Table 9. Characteristics of Project Management within AROs and CROs (cont) 
ARO, N(%) CRO, N(%) 
Training opportunities offered to 
project managers in the 
organization* 
Gantt chart, PERT, or other chart 2 (18) 21 (64) 
system 
Project Management Software 6 (55) 25 (76) 
Risk Management 3 (27) 25 (76) 
Project planning 9 (82) 30 (91) 
Professional certification (PMP, etc) 4 (36) 11 (33) 
Budget creation 6 (55) 21 (64) 
Timeline creation 6 (55) 23 (70) 
Communication Plan 6 (55) 27 (81) 
Operations Plan 7 (64) 20 (61) 
Project Management training from 3 (27) 12 (36) 
outside vendor 
Other 2 (18) 3 (9) 
Answered Question 11 (35)" 33(70)" 
Question not answered 20(65)" 14(30)" 
Approximate rate of annual 
turnover among project managers 
0-10% 15 (65) 26 (77) 
11-20% 6 (26) 7 (21) 
21-25% 2 (9) 1 (3) 
>25% 0 (0) 0 (0) 
Answered Question 23(74 )" 72(72)" 
Question not answered 8(26)" 13(28)" 
*Answer opt1on Included "Please select all that apply". "Based on total 
number of respondents for each question. 
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Table 9. Characteristics of Project Management within AROs and CROs (cont). 
ARO, N(%) CRO, N(%) 
Primary roles and responsibilities of 
project managers* 
Budget Development 7 (30) 12 (32) 
Budget Management 9 (39) 32 (87) 
Managing Resources 19 (83) 26 (70) 
Leading team meetings 17 (74) 34 (92) 
Creating timelines 14 (61) 25 (68) 
Managing timelines 17 (74) 34 (92) 
Draft sections of contract 2 (9) 10 (27) 
Review & comment on contract drafts 10 (44) 20 (54) 
Comment & review Request for 10 (44) 21 (57) 
Proposals (RFPs) 
Managing project activities 20 (87) 35 (95) 
Tracking project activities 21 (91) 34 (92) 
Oversight of GRAs & project support 13 (57) 19 (51) 
staff 
Other 4 (17) 3 (8) 
Answered Question 23(7 4 )" 37(79)" 
Question not answered 8(26)" 1 0(21 )" 
Most important knowledge areas for 
project managers3 
Drug Development 4 (17) 5 (14) 
Therapeutic Area 8 (35) 16 (44) 
Integration of Deliverables by team 4 (17) 8 (22) 
Project scope 6 (26) 4 (11) 
Time Management 11 (48) 13 (36) 
Budget Management 5 (22) 14 (39) 
Quality assessment 13 (57) 12 (33) 
Resource Allocation 4 (17) 1 (3) 
Risk Management 2 (9) 11 (31) 
Negotiation 0 (0) 1 (3) 
Communication 14 (61) 21 (58) 
Answered Question 23(7 4 )" 36(77)" 
Question not answered 8(26)" 11 (23)" 
*Answer opt1on mcluded "Please select all that apply" . "Based on total number of 
respondents for each question. 3 Piease select only three. 
Table 9. Characteristics of Project Management within AROs and CROs (cant). 
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ARO, N(%) CRO, N(%) 
Salary Range of Project Managers 
within the Organization (USD) 
<$40,000 1 (5) 2 (6) 
$40 '000-$50' 000 3 (14) 2 (6) 
$51,000-$60,000 0 (0) 0 (0) 
$61,000-$70,000 5 (23) 5 (14) 
$71 ,000-$80,000 3 (14) 3 (8) 
$81,000-$90,000 0 (0) 0 (0) 
$91 ,000-$100,000 9 (41) 9 (25) 
>$100,000 1 (5) 15 (42) 
Answered Question 22(71 )A 36(77)" 
Question not answered 9(29)" 11 (23)" 
"Based on total number of respondents. 
Table 10. Training opportunities and training resources offered to Project 
Managers within the organization. 
ARO 
• Most are experienced so they have 
basic training in Project 
Management and Therapeutic 
Areas, they are expected to use 
their previous experience. 
• Shadowing period with Project 
Director of the trial. 
• Documented 90-day training 
period for all Project Managers in 
the organization . 
CRO 
• Most Project Managers 
move from the CRA rank, 
and training is based on the 
differences between 
monitoring and Project 
Management in a didactic 
format 
• Shadowing more senior level 
employees, PMI or PMP 
certification is offered if the 
budget will allow. 
• Class-room format training 
on project management 
SOPs and therapeutic area 
Table 11. Relationship with sponsor companies 
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ARO 
• Great. We have worked with the 
same sponsor more than once 
• Average. We've had some 
difficulties in the past with sponsor 
companies not understanding the 
academic culture. Also, sponsors 
have not been up front with their 
expectations in the past. 
• Great. Given that we view the 
trials as collaborations between 
our organization and the sponsor 
we have worked with several 
sponsor companies on more than 
one occasion. 
CRO 
• Great. Project Managers 
and Business Development 
contribute to keeping the 
lines of communication open. 
• Great. There are no major 
problems, but there is always 
room for improvement. 
• Great. Project Managers 
have a lot of experience, and 
excellent communication 
skills in our organization. 
Table 12. Risk Management in the organization. 
ARO 
• Important. Senior management 
does this, not Project Managers. 
• Very important. Contingency 
plans are done in the beginning of 
a trial and then updates to these 
plans are done at certain intervals 
during the project. 
• Important. Risk Management is 
project-dependent and also 
depends on the amount of 
personal experience the Project 
Manager has. 
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CRO 
• Very important. Project 
Manager is solely 
responsible for developing 
the Risk Management Plan. 
• Very important. Project 
Manager and Senior 
Management develop plan in 
the beginning of the trial. 
• Very important. This is a 
shared responsibility 
between sponsor and Project 
Manager. This is done 
primarily in the RFP process. 
Table 13. Roles and Responsibilities of Project Managers in the organization. 
ARO 
• Satisfied. There is a low rate of 
turnover in our organization. 
• Very good. We standardized our 
job descriptions 5 years ago, so 
the overall satisfaction has 
improved greatly. 
• Very good. We have a supportive 
Senior Management team. 
CRO 
• Satisfied. This is constantly 
changing due to the 
sponsor's needs and 
requirements. 
• Satisfied. Roles and 
responsibilities depend on 
client's needs. 
• Satisfied. Roles and 
responsibilities depend on 
the client's needs. 
Table 14. Roles and responsibilities of Project Managers in comparison to 
salary. 
ARO 
• Pretty good. Even though I know 
we are less than the industry 
standard. 
• Pretty good. We have a low 
turnover rate, even though we 
know we are paid less. 
• Pretty good. Given that most of 
our Project Manager's come from 
industry. 
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CRO 
• Good. We try to be 
competitive with industry 
standards. 
• Good. We are competitive 
and it also depends on 
experience. 
• Good. This also depends on 
the level of previous 
experience. 
Table 15. Satisfaction with communication between Project Managers and 
CRAs/project staff in the organization. 
ARO 
• Great. We communicate very well. 
• Most likely very good. I have 
never heard of any major 
problems. 
• Good. This has improved by 
refining the channels of 
communication in the organization. 
CRO 
• Good. We have a refined 
communication plan. There 
is constant communication 
with CRAs. 
• Great. Most Project 
Managers have CRA 
experience so they know 
what it is like, and some of 
the problems that are 
experienced . 
• Great. We have developed 
a very specific 
communication plan . We 
have never had any 
problems that I am aware of. 
Table 16. Relationship between Senior Management and Project Management. 
ARO CRO 
• Great. Senior Management is very • Great. Senior Management 
involved. There are bi-weekly is highly involved. There are 
update meetings. monthly progress meetings 
where Project Managers 
present the progress of their 
project. 
• Great. Because we are a small • Pretty good. It is tough for 
organization , they are able to be them to be involved. We are 
as involved as possible depending developing a process that 
on the project. If necessary, even will allow Senior 
on a daily basis. Management to be more 
available. 
• Great. There are project progress • Great. Project update 
meetings where Senior meetings are done 
Management offers guidance for periodically. 
any problems if necessary. 
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Survey 
Section 1: This series of questions is aimed at understanding your role within 
your current organization and your experience in Project Management. 
1. Please define your role in your current organization. Is your primary 
responsibility within your organization to manage projects (i.e. clinical studies or 
clinical trials)? 
Yes 
No 
2. How many years have you been at your current organization? 
0-5 
6-10 
11-15 
3. What is your highest level of education and degree obtained? 
BAIBS 
MS/MS 
PhD 
PharmD 
MBA 
DVM 
MD 
DO 
Other (please specify) 
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4. Please indicate whether you have any of the following professional 
certification 
PMP 
CAPM 
PgMP 
PMI-SP 
PPMC 
Six-Sigma 
CCRP 
CCRA 
CCRC 
CPI 
CTI 
Other (please specify 
5. How many years of experience do you have in project management? 
0-5 
6-10 
11-15 
>15 
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Section 2: The purpose of this section is to understand your organization and the 
types of clinical trials and studies that are done within your organization. 
6. Which of the following best describes your organization? 
Academic Research Organization (ARO) 
Contract Research Organization (CRO) 
None of these 
7. Please select the therapeutic areas in which your organization conducts 
research. Please select all that apply. 
Cardiology 
Hematology 
Endocrinology 
Ophthalmology 
GI/Hepatology 
Immunology 
Nephrology 
Otolaryngology 
Neuroscience (CNS) 
Infectious Diseases 
Oncology 
Pediatrics 
Other (Please specify) 
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8. Please select the type of trials/projects your organization conducts. Please 
select all that apply: 
Clinical Trials (drugs/biologics) 
Clinical Trials (devices/diagnostics) 
Epidemiological Studies 
9. Please indicate the stages of clinical trials within your organization: 
II 
Ill 
IV /Post-marketing 
Medical Devices/Diagnostics 
Pivotal Device Studies 
NSR Studies (medical devices only) 
SR Studies (medical devices only) 
Combination products (i.e. drug-coated stent) 
1 0. What is the total number of employees in your organization? 
<250 
250-500 
>500 
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11. Please consider the following organizational structures. 
Which of the following organizational structures best reflects that of your 
organization? 
A 
B 
c 
None of these 
c 
-
........ 
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8 
-............ 
12. Of those trials currently in progress, please indicate the number of mega-
trials your organization conducts (i.e. a trial or study, with more than 10,000 
globally distributed subjects) 
none 
1-3 
3-5 
>6 
13. What region(s) does your organization conduct clinical trials/studies? Please 
select all that apply 
USA 
Europe 
Asia 
Latin America 
Australia 
Canada 
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14. What services does your organization provide? Please select all that apply. 
Academic Leadership 
Laboratory Services & Manufacturing 
Steering Committee Leadership 
Study Design 
Site Recruitment 
Site Monitoring 
Specialty Facilities (i .e. core labs, etc) 
Biostatistics 
DSMB/DMC 
Analytical Testing 
IRB 
Data Management 
Pharmacovigilance/Safety Monitoring 
Regulatory Affairs 
Auditing 
Other (please specify) 
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Section 3: This section's purpose is to understand how project managers 
operate within your organization. 
15. How many project managers are employed in your organization? 
0-5 
6-10 
11-15 
>15 
16. Which title best describes the head of project management in your 
organization? 
Head/Manager 
Vice President 
Director 
Other (please specify) 
17. How many project team members (i .e. CRAs, project assistants, etc) are 
employed at your organization? 
0-10 
11-20 
>20 
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18. Please indicate how many project managers and CRAs are allocated in the 
following scenarios. 
Scenario # Project Managers # CRAs/Project Staff 
Several countries 1,2,3,4,5,>5 0-5,6-10, 11-15, 16-20, >20 
with >1 0,000 
subjects 
Several countries 1,2,3,4,5,>5 0-5,6-10,11-15,16-20, >20 
with 1 ,000-10,000 
subjects 
Several countries 1,2, 3,4,5, >5 0-5, 6-10, 11-15, 16-20, >20 
with 500-1,000 
subjects 
1 country with 500- 1,2,3,4,5, >5 0-5,6-10,11-15, 16-20, >20 
1,000 subjects 
1 country with <500 1,2,3,4,5, >5 0-5,6-10,11-15, 16-20, >20 
subjects 
19. On average, how many projects are assigned to a project manager at one 
time? 
1 
2 
3 
4 
>4 
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20. How are project prioritized in your organization? Please select the scenario 
that is most likely to occur in your organization. 
Contract Value 
Margins 
Size of project 
Duration of project 
Projected success of project 
Resource allocation for project 
Other (please specify) 
21. Are there standard procedures (SOPs; standard operating procedures), 
methods, or strategies used for project managers in your organization? 
Yes 
No 
Not Sure 
22. Does your organization offer formal training on its formal procedures, SOPs, 
methods, and strategies for project management? 
Yes 
No 
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23. Please indicate which of the following training opportunities are offered to 
project managers in your organization. Please select all that apply. 
Gantt chart, PERT chart, or other charting system 
Project management software (Microsoft Project, etc) 
Risk Management 
Project Planning 
Professional certification (PMP, etc) 
Budget creation 
Timeline creation 
Communication Plan 
Operations Plan 
Project management training from outside vendor 
Other (please specify) 
24. What is the approximate amount of annual turnover among project 
managers in your organization? 
0-10% 
11-20% 
21-25% 
>25% 
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25. What are the primary roles and responsibilities of project managers in your 
organization? Please select all that apply. 
Budget development 
Budget management 
Managing resources 
Leading team meetings 
Creating timelines 
Managing timelines 
Draft sections of contract 
Review and comment on contract drafts 
Comment & Review Request for Proposals (RFPs) 
Managing project activities 
Tracking project activities 
Oversight of GRAs 
Other (please specify) 
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26. Which of the following are the 3 most important knowledge areas for project 
managers in your organization? Please select only three. 
Drug Development 
Therapeutic Area 
Integration of Deliverables by project team 
Project Scope 
Time Management 
Budget Management 
Project Quality (assessment) 
Resource Allocation 
Risk Management 
Negotiation 
Communication 
27. What is the approximate salary of a project manager at your organization? 
<$40,000 
$40,000-$50,000 
$51,000-$60,000 
$61,000-$70,000 
$71,000-$80,000 
$81,000-$90,000 
$91,000-$100,000 
>$100,000 
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28. To receive a summary of the survey results and to be entered to win a $100 
American Express Gift Card, please provide your name and contact information 
in the field below. 
29. Would you be willing to participate in a brief phone interview to further 
discuss project management at your organization? 
Yes 
No 
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Interview 
1. Please describe the level of training and resources your organization 
provides to project manager 
a. Too much training/resources- which in your opinion are the 
priorities? Does training interfere with the completing required daily 
basis? 
b. Too little training/resources- what in your opinion could be provided 
to better prepare Project Managers? 
c. No training/resources- what training do you feel would be beneficial 
for your organization to provide, and why? 
2. Please describe your organization's relationship with the sponsor 
companies. 
a. Positive- please explain why you think that is. 
b. Average- Please explain what could be done to improve the 
relationship , and why? 
c. Poor/Negative- What could be done to improve? 
i. Please give your opinion: Why do you think the relationship 
is strained? 
3. Does your organization have a process or plan implemented to 
assess Risk Management of projects? 
a. Yes- please describe 
b. No- please explain why there is not a plan 
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i. If No: Do you think there should be a Risk Management 
Plan implemented at your organization for project 
managers? 
ii. Do you think Risk Management is important? Why or Why 
not? 
4. Please describe your level of satisfaction with: 
a. The primary roles and responsibilities of project managers in your 
organization 
i. If not satisfied- What could be done to improve? 
b. The primary roles and responsibilities of project managers in your 
organization as compared to your salary. Do you feel they are in 
line with one another? 
i. If not satisfied- What could be done to improve? 
c. The communication between CRAs/project staff with project 
managers 
i. If not satisfied- What could be done to improve? 
d. Relationship between senior management and project managers in 
your organization 
i. If not satisfied- What could be done to improve? 
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LIST OF ABBREVIATED JOURNAL TITLES 
ACT Applied Clinical Trials 
Ann Pharmacother The Annals of Pharmacotherapy 
Blood Blood 
Circulation Circulation 
CMAJ Canadian Medical Association Journal 
Grit Care Med Critical Care Medicine 
Drug Discov Today Drug Discovery Today 
JAMA Journal of the American Medical Association 
J Appl Psycho! Journal of Applied Psychology 
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J Clin Oneal The Journal of Clinical Oncology 
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